Increased risk of idiopathic pulmonary fibrosis in inflammatory bowel disease: A nationwide study.
Claims data
Crohn's disease
Idiopathic pulmonary fibrosis
Inflammatory bowel disease
Ulcerative colitis
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
17
01
2019
revised:
27
07
2019
accepted:
12
08
2019
pubmed:
20
8
2019
medline:
28
8
2020
entrez:
18
8
2019
Statut:
ppublish
Résumé
The relationship between inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF) remains unclear. We evaluated the risk for developing IPF in patients with IBD using a nationwide population-based study. Using claims data from the National Health Insurance service in Korea, patients with IBD, including Crohn's disease (CD) and ulcerative colitis (UC), were identified through both the 10th revision of the International Statistical Classification of Diseases and Related Health Problems and rare and intractable disease program codes from January 2010 to December 2013. We compared 38 921 IBD patients with age-matched and sex-matched individuals without IBD in a ratio of 1:3. Patients with newly diagnosed IPF were identified by both the 10th revision of the International Statistical Classification of Diseases and Related Health Problems and rare and intractable disease registration codes. During a mean 4.9-year follow-up, the incidence of IPF in patients with IBD was 33.21 per 100 000 person-years. The overall risk of IPF was significantly higher in IBD patients than in non-IBD controls (hazard ratio [HR], 1.62; 95% confidence interval [CI], 1.20-2.20; P = 0.003). In patients with CD, the incidence (per 100 000 person-years) of IPF was 26.04; in controls, the incidence was 9.15 (HR, 2.89; 95% CI, 1.46-5.72; P = 0.002). The incidence of IPF in patients with UC tended to be higher than in controls (36.66 vs 26.54 per 100 000 person-years; 95% CI, 0.99-1.99; HR, 1.41; P = 0.066). The risk of developing IPF in patients with IBD was higher in male patients than in female patients (P = 0.093 in CD; P = 0.147 in UC by interaction analysis). Patients with IBD, especially CD, have an increased risk of developing IPF.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
The relationship between inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF) remains unclear. We evaluated the risk for developing IPF in patients with IBD using a nationwide population-based study.
METHODS
METHODS
Using claims data from the National Health Insurance service in Korea, patients with IBD, including Crohn's disease (CD) and ulcerative colitis (UC), were identified through both the 10th revision of the International Statistical Classification of Diseases and Related Health Problems and rare and intractable disease program codes from January 2010 to December 2013. We compared 38 921 IBD patients with age-matched and sex-matched individuals without IBD in a ratio of 1:3. Patients with newly diagnosed IPF were identified by both the 10th revision of the International Statistical Classification of Diseases and Related Health Problems and rare and intractable disease registration codes.
RESULTS
RESULTS
During a mean 4.9-year follow-up, the incidence of IPF in patients with IBD was 33.21 per 100 000 person-years. The overall risk of IPF was significantly higher in IBD patients than in non-IBD controls (hazard ratio [HR], 1.62; 95% confidence interval [CI], 1.20-2.20; P = 0.003). In patients with CD, the incidence (per 100 000 person-years) of IPF was 26.04; in controls, the incidence was 9.15 (HR, 2.89; 95% CI, 1.46-5.72; P = 0.002). The incidence of IPF in patients with UC tended to be higher than in controls (36.66 vs 26.54 per 100 000 person-years; 95% CI, 0.99-1.99; HR, 1.41; P = 0.066). The risk of developing IPF in patients with IBD was higher in male patients than in female patients (P = 0.093 in CD; P = 0.147 in UC by interaction analysis).
CONCLUSIONS
CONCLUSIONS
Patients with IBD, especially CD, have an increased risk of developing IPF.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
249-255Informations de copyright
© 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Raghu G, Collard HR, Egan JJ et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788-824.
Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 2018; 378: 1811-1823.
Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet (London, England). 2017; 389: 1941-1952.
Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel Dis. 2006; 12: S3-S9.
Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J. Gastroenterol. 2006; 12: 4819-4831.
Kraft SC, Earle RH, Roesler M, Esterly JR. Unexplained bronchopulmonary disease with inflammatory bowel disease. Arch. Intern. Med. 1976; 136: 454-459.
Mahadeva R, Walsh G, Flower CD, Shneerson JM. Clinical and radiological characteristics of lung disease in inflammatory bowel disease. Eur. Respir. J. 2000; 15: 41-48.
Colia R, Corrado A, Cantatore FP. Rheumatologic and extraintestinal manifestations of inflammatory bowel diseases. Ann. Med. 2016; 48: 577-585.
Balestra DJ, Balestra ST, Wasson JH. Ulcerative colitis and steroid-responsive, diffuse interstitial lung disease: a trial of N = 1. JAMA 1988; 260: 62-64.
McKee AL, Rajapaksa A, Kalish PE, Pitchumoni CS. Severe interstitial pulmonary fibrosis in a patient with chronic ulcerative colitis. Am. J. Gastroenterol. 1983; 78: 86-89.
Hotermans G, Benard A, Guenanen H, Demarcq-Delerue G, Malart T, Wallaert B. Nongranulomatous interstitial lung disease in Crohn's disease. Eur. Respir. J. 1996; 9: 380-382.
Black H, Mendoza M, Murin S. Thoracic manifestations of inflammatory bowel disease. Chest 2007; 131: 524-532.
Lee YH, Han K, Ko SH, Ko KS, Lee KU. Data analytic process of a nationwide population-based study using national health information database established by National Health Insurance Service. Diabetes Metab. J. 2016; 40: 79-82.
Yeom M. Direction of policy and management for rare intractable disease patients support program. Health Insur. Rev. Assess Serv. (HIRA) Policy Rev. 2009; 3: 6-10.
Kim HJ, Hann HJ, Hong SN et al. Incidence and natural course of inflammatory bowel disease in Korea, 2006-2012: a nationwide population-based study. Inflamm. Bowel Dis. 2015; 21: 623-630.
Lee SR, Choi EK, Rhee TM et al. Evaluation of the association between diabetic retinopathy and the incidence of atrial fibrillation: a nationwide population-based study. Int. J. Cardiol. 2016; 223: 953-957.
Choi CW, Eun SH, Choi KH, Bae JM. Increased risk of comorbid rheumatic disorders in vitiligo patients: a nationwide population-based study. J. Dermatol. 2017; 44: 909-913.
Kang SY, Song WJ, Cho SH, Chang YS. Time trends of the prevalence of allergic diseases in Korea: a systematic literature review. Asia Pac. Allergy 2018; 8: e8.
Park S, Chun J, Han KD et al. Increased end-stage renal disease risk in patients with inflammatory bowel disease: a nationwide population-based study. World J. Gastroenterol. 2018; 24: 4798-4808.
Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc. Am. Thorac. Soc. 2006; 3: 285-292.
Camus P, Piard F, Ashcroft T, Gal AA, Colby TV. The lung in inflammatory bowel disease. Medicine 1993; 72: 151-183.
Tzanakis N, Bouros D, Samiou M et al. Lung function in patients with inflammatory bowel disease. Respir. Med. 1998; 92: 516-522.
Spira A, Grossman R, Balter M. Large airway disease associated with inflammatory bowel disease. Chest 1998; 113: 1723-1726.
Herrlinger KR, Noftz MK, Dalhoff K, Ludwig D, Stange EF, Fellermann K. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am. J. Gastroenterol. 2002; 97: 377-381.
Douglas JG, McDonald CF, Leslie MJ, Gillon J, Crompton GK, McHardy GJ. Respiratory impairment in inflammatory bowel disease: does it vary with disease activity? Respir. Med. 1989; 83: 389-394.
Ates F, Karincaoglu M, Hacievliyagil SS, Yalniz M, Seckin Y. Alterations in the pulmonary function tests of inflammatory bowel diseases. Turk. J. Gastroenterol. 2011; 22: 293-299.
Lakatos L, Pandur T, David G et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J. Gastroenterol. 2003; 9: 2300-2307.
Lee YM, Kaplan MM. Management of primary sclerosing cholangitis. Am. J. Gastroenterol. 2002; 97: 528-534.
Cioffi M, Rosa AD, Serao R, Picone I, Vietri MT. Laboratory markers in ulcerative colitis: current insights and future advances. World J. Gastrointest. Pathophysiol. 2015; 6: 13-22.
Gross V, Andus T, Caesar I, Roth M, Scholmerich J. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992; 102: 514-519.
Storch I, Sachar D, Katz S. Pulmonary manifestations of inflammatory bowel disease. Inflamm. Bowel Dis. 2003; 9: 104-115.
Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005; 129: 827-836.
Poletti V, Tomassetti S, Ravaglia C. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 2018; 379: 797.
Cozzi D, Moroni C, Addeo G et al. Radiological patterns of lung involvement in inflammatory bowel disease. Gastroenterol. Res. Pract. 2018; 2018: 10.
Byun JM, Lee CK, Rhee SY et al. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor. Scand. J. Gastroenterol. 2015; 50: 312-320.
Schwaiblmair M, Behr W, Haeckel T, Markl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. Open Respir. Med. J. 2012; 6: 63-74.
Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 1994; 150: 967-972.
Huang PH, Kuo CJ, Lin CW et al. Mesalazine-related lung disease in a patient with ulcerative colitis: a case report. Medicine 2018; 97: e13242.
Shindoh Y, Horaguchi R, Hayashi K, Suda Y, Iijima H, Shindoh C. A case of lung injury induced by long-term administration of mesalazine. Nihon Kokyuki Gakkai zasshi = J. Jpn. Respir. Soc. 2011; 49: 861-866.
Sharma A, Provenzale D, McKusick A, Kaplan MM. Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis. Gastroenterology 1994; 107: 266-270.
Bedrossian CW, Miller WC, Luna MA. Methotrexate-induced diffuse interstitial pulmonary fibrosis. South. Med. J. 1979; 72: 313-318.
Tanigawa K, Sugiyama K, Matsuyama H et al. Mesalazine-induced eosinophilic pneumonia. Respiration 1999; 66: 69-72.
Salerno SM, Ormseth EJ, Roth BJ, Meyer CA, Christensen ED, Dillard TA. Sulfasalazine pulmonary toxicity in ulcerative colitis mimicking clinical features of Wegener's granulomatosis. Chest 1996; 110: 556-559.
Moss SF, Ind PW. Time course of recovery of lung function in sulphasalazine-induced alveolitis. Respir. Med. 1991; 85: 73-75.
Uittenbogaart SB, Klemt-Kropp M. Mesalazine and sulphasalazine for Crohn's disease: few indications, severe adverse reactions. Ned. Tijdschr. Geneeskd. 2011; 155: A3842.
van der Heide F, Dijkstra A, Weersma RK et al. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm. Bowel Dis. 2009; 15: 1199-1207.